{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=36", "query": { "condition": "Urinary Bladder Neoplasm", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 941, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T13:58:13.502Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003759", "title": "AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "BCG vaccine", "type": "BIOLOGICAL" }, { "name": "valrubicin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Anthra Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": "2002-11", "has_results": false, "last_update_posted_date": "2013-01-31", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003759" }, { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT05052372", "title": "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Transitional Cell Carcinoma", "Platinum-Resistant Urothelial Carcinoma", "Bladder Urothelial Carcinoma", "FGFR Mutation", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "FGFR2 Amplification", "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Refractory Bladder Carcinoma", "Refractory Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Balversa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-11-21", "completion_date": "2022-12-20", "has_results": false, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 1, "location_summary": "Raleigh, North Carolina", "locations": [ { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052372" }, { "nct_id": "NCT00014456", "title": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Carcinoma of Unknown Primary", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Lung Cancer", "Melanoma (Skin)", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00014456" }, { "nct_id": "NCT07225127", "title": "Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer", "Recurrent Bladder Cancer", "Non-muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [], "intervention_types": [], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-11-03", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 6, "location_summary": "Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225127" }, { "nct_id": "NCT02845323", "title": "Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Nivolumab in combination with Urelumab", "type": "DRUG" }, { "name": "Nivolumab monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-05-16", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02845323" }, { "nct_id": "NCT01004224", "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3", "Squamous Lung Cancer With FGFR1 Amplification", "Bladder Cancer With FGFR3 Mutation or Fusion", "Advanced Solid Tumors With FGFR1 Amplication", "Advanced Solid Tumors With FGFR2 Amplication", "Advanced Solid Tumors With FGFR3 Mutation" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2009-12-11", "completion_date": "2018-10-08", "has_results": false, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004224" }, { "nct_id": "NCT02281383", "title": "Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "High Risk Superficial" ], "interventions": [ { "name": "Bacillus Calmette-Guérin (BCG)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2014-10", "completion_date": "2022-02-24", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281383" }, { "nct_id": "NCT04548193", "title": "Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage 0a Bladder Cancer AJCC v8", "Stage 0is Bladder Cancer AJCC v8", "Stage I Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Behavioral Dietary Intervention", "type": "BEHAVIORAL" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2021-04-05", "completion_date": "2024-04-04", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04548193" }, { "nct_id": "NCT00006034", "title": "Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Intracel", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-11-02T13:58:13.502Z", "location_count": 1, "location_summary": "Frederick, Maryland", "locations": [ { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006034" } ] }